Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL543661 | 0.86 | NPC1 (0.36) | CNR1CYP2C19GAACYP2C9MAPT | |
| SCHEMBL14767535 | 0.70 | CYP2C19 (0.34) | CNR1CYP2C19GAACYP2C9ELANE | |
| SCHEMBL543791 | 0.70 | ELANE (0.36) | CYP2C19CYP2C9ELANECYP1A2 | |
| SCHEMBL543867 | 0.68 | ELANE (0.37) | GAAELANELMNAMAPT | |
| SCHEMBL544235 | 0.61 | ELANE (0.39) | GAAELANEMAPTMEN1KMT2A | |
| SCHEMBL543513 | 0.61 | ALDH1A1 (0.48) | GAAELANEHPGD | |
| Ethylbenzene SCHEMBL11182786 | 0.60 | CNR1 (0.41) | CNR1CYP2C19GAACYP2C9LMNA | |
| SCHEMBL893095 | 0.60 | ELANE (0.35) | ELANE | |
| SCHEMBL11182780 | 0.59 | CNR1 (0.40) | CNR1CYP2C19CYP2C9LMNAMAPT | |
| SCHEMBL544341 | 0.59 | ELANE (0.34) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767824-B2 | Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2010-08-03 | — | — | US | claimed |
| US-20060205742-A1 | Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-09-14 | — | — | US | claimed |
| EP-1357124-B1 | HETEROCYCLIC COMPOUNDS AND CEREBRAL FUNCTION IMPROVERS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ZENYAKU KOGYO KK (JP) | 2005-08-03 | — | — | EP | claimed |
| US-20040048879-A1 | Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2004-03-11 | — | — | US | claimed |
| EP-1357124-A1 | HETEROCYCLIC COMPOUNDS AND CEREBRAL FUNCTION IMPROVERS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2003-10-29 | — | — | EP | claimed |
| EP-2388000-B1 | Neuroprotectant containing heterocyclic compound having specific structure | ZENYAKU KOGYO KK (JP) | 2016-04-06 | — | — | EP | disclosed |
| EP-2077836-B1 | AMYLOID BETA DEPOSITION INHIBITOR CONTAINING SPIRO-HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KK (JP) | 2016-03-09 | — | — | EP | disclosed |
| EP-2388001-B1 | Age retardant containing heterocyclic compound having specific structure | ZENYAKU KOGYO KK (JP) | 2015-12-16 | — | — | EP | disclosed |
| EP-2388001-B1 | Age retardant containing heterocyclic compound having specific structure | ZENYAKU KOGYO KK (JP) | 2015-12-16 | — | — | EP | disclosed |
| US-9089561-B2 | Methods for treating depression, neurodegeneration, inhibiting amyloid β deposition, delaying senescence, and extending life spans with heterocyclic compounds | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2015-07-28 | — | — | US | disclosed |
| US-9089561-B2 | Methods for treating depression, neurodegeneration, inhibiting amyloid β deposition, delaying senescence, and extending life spans with heterocyclic compounds | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2015-07-28 | — | — | US | disclosed |
| US-9089561-B2 | Methods for treating depression, neurodegeneration, inhibiting amyloid β deposition, delaying senescence, and extending life spans with heterocyclic compounds | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2015-07-28 | — | — | US | disclosed |
| US-20080103158-A1 | spiro[imidazo[1,2-a]pyridin-2(3H)-one-3,2'-indan]; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2008-05-01 | — | — | US | disclosed |
| WO-2008047952-A2 | ANTIDEPRESSANT, NEUROPROTECTANT, AMYLOID BETA DEPOSITION INHIBITOR OR AGE RETARDANT CONTAINING HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008047951-A2 | AN ALZHEIMER' S DISEASE PROGRESSION INHIBITOR CONTAINING HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2008-04-24 | — | — | WO | disclosed |
| US-7141579-B2 | Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-11-28 | — | — | US | disclosed |
| US-20060205742-A1 | Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-09-14 | — | — | US | disclosed |
| EP-1357124-B1 | HETEROCYCLIC COMPOUNDS AND CEREBRAL FUNCTION IMPROVERS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ZENYAKU KOGYO KK (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-20040048879-A1 | Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1357124-A1 | HETEROCYCLIC COMPOUNDS AND CEREBRAL FUNCTION IMPROVERS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2003-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205742-A1 | Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient | CBR3, CBR1, C1R | CNR1 5/4885CYP2C19 1002/4885GAA 2278/4885 |
| US-20080103158-A1 | spiro[imidazo[1,2-a]pyridin-2(3H)-one-3,2'-indan]; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | PSEN1, PSEN2, GRN | CNR1 1557/4885CYP2C19 1147/4885GAA 765/4885 |
| US-20040048879-A1 | Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient | CBR1, CBR3, CHAT | CNR1 4/4885CYP2C19 1524/4885GAA 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.